orantinib has been researched along with su 5614 in 1 studies
| Studies (orantinib) | Trials (orantinib) | Recent Studies (post-2010) (orantinib) | Studies (su 5614) | Trials (su 5614) | Recent Studies (post-2010) (su 5614) |
|---|---|---|---|---|---|
| 110 | 19 | 36 | 26 | 0 | 3 |
| Protein | Taxonomy | orantinib (IC50) | su 5614 (IC50) |
|---|---|---|---|
| Proto-oncogene tyrosine-protein kinase receptor Ret | Homo sapiens (human) | 1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cherrington, JM; Knox, SJ; Laird, D; Ning, S | 1 |
1 other study(ies) available for orantinib and su 5614
| Article | Year |
|---|---|
The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Fibroblast Growth Factor 2; Gene Expression Regulation, Neoplastic; Indoles; Lymphokines; Mice; Mice, Inbred C3H; Neoplasm Proteins; Oxindoles; Platelet-Derived Growth Factor; Propionates; Pyrroles; Radiation-Sensitizing Agents; Radioisotope Teletherapy; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; RNA, Messenger; RNA, Neoplasm; Specific Pathogen-Free Organisms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |